WAM
CTOR

Wolverine Asset Management’s Citius Oncology CTOR Stock Holding History

Wolverine Asset Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-407,333
Closed -$4.62M – 1810
2024
Q2 		$4.62M Sell
407,333
-5,219
-1% -$58.5K 0.05% 309
2024
Q1 		$4.56M Sell
412,552
-154,161
-27% -$1.69M 0.05% 301
2023
Q4 		$6.2M Buy
566,713
+368
+0.1% +$4.01K 0.05% 311
2023
Q3 		$6.1M Sell
566,345
-11,133
-2% -$119K 0.07% 277
2023
Q2 		$6.08M Sell
577,478
-3,449
-0.6% -$36K 0.07% 253
2023
Q1 		$6.04M Buy
+580,927
New +$5.97M 0.07% 295

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wolverine Asset Management's CTOR Position: Q3 2024 in Review

Wolverine Asset Management sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 407,333 shares — an estimated $4.62M sold.

Wolverine Asset Management first reported a position in CTOR in Q1 2023 and held it in 6 quarters. The position peaked at $6.2M in Q4 2023. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • Wolverine Asset Management reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • Wolverine Asset Management sold 407,333 Citius Oncology shares in Q3 2024, an estimated $4.62M.
  • Wolverine Asset Management first reported a position in Citius Oncology in Q1 2023 and held it in 6 quarters.
  • Wolverine Asset Management's Citius Oncology position peaked at $6.2M in Q4 2023.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on Wolverine Asset Management's 13F filing for Q3 2024, filed 4 Nov 2024.